

DR. ANDREAS MÜHLER



Dr. Andreas Müller is the CMO of Immunic AG. He received his medical degree (MD) from Humboldt-University in Berlin, Germany and an MBA degree from Duke University. After a short period in clinical work, Andreas has worked within the pharmaceutical industry since 1992, most of it in the US, with leadership positions in preclinical and clinical development, business development & licensing and marketing. During this period, Andreas was involved in several clinical programs and regulatory submissions (IND, NDA) as well as several large licensing deals.

Since 2003, Andreas developed and managed multiple medical companies in the US. Among them were 3TP LLC d/b/a CAD Sciences (White Plains, NY), a medical software company developing an imaging solution for early detection of breast and prostate cancer, which was subsequently sold to iCAD Medical in 2008. Another startup was Collectar Inc. (Madison, WI), a biotech company developing new cancer therapeutics and cancer imaging agents, in which Andreas managed the initial development of the lead compound until IND filing.

Andreas was also President & CEO of MicroMRI Inc (Langhorne, PA), a medical device company developing solutions for improved osteoporosis diagnosis and therapy monitoring based on bone micro-architecture. He has been on the Board of Directors of multiple small medical technology companies.

After moving to Munich in 2009, Andreas became Managing Director of the small healthcare private equity fund Palladius Healthcare GmbH (Munich, Germany) which acquired distressed medical technology companies. As part of this fund, Andreas was involved in the management of portfolio companies.

Thereafter, Andreas worked as interim manager and has been doing multiple interim management projects for pharmaceutical and medical device companies. Most of these assignments involved managing large clinical trials in the oncology area. Additionally, Andreas was also closely involved in the launch of several major pharmaceuticals in Germany, among them Brentuximabvedotin (for treatment of Hodgkin lymphoma and some NHL), Vedolizumab (an antibody for treatment of inflammatory bowel disease) and an oral budesonide as treatment for ulcerative colitis.

SHORT BIO

SKILLS

Within the pharmaceutical industry since 1992

EXPERIENCE

Held multiple interim management positions for pharmaceutical and medical device companies

QUALIFICATION

Developed and managed multiple medical companies in the US and Germany

MOTIVATION

Developing innovative therapies for patients with debilitating diseases